Mechanisms and functional consequences of PDEF protein expression loss during prostate cancer progression

Prostate

Volumn 71, Issue 16, 2011, Pages 1723-1735

  Turner, David P ^a,b   Findlay, Victoria J ^a,b   Moussa, Omar ^a,b   Semenchenko, Victor I ^a,b,c   Watson, Patricia M ^a,b   Larue, Amanda C ^a,b   Desouki, Mohamed M ^a   Fraig, Mostafa ^a,b,d   Watson, Dennis K ^a,b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c NuGEN   (United States)

^d University of Louisville School of Medicine   (United States)

Author keywords

Ets; invasion; microRNA; migration; PDEF; prostate cancer

Indexed keywords

MESSENGER RNA; MICRORNA; MICRORNA 204; PROSTATE DERIVED EPITHELIAL FACTOR; RNA; SURVIVIN; TRANSCRIPTION FACTOR ETS; TRANSCRIPTION FACTOR SLUG; UNCLASSIFIED DRUG; UROKINASE;

3' UNTRANSLATED REGION; APOPTOSIS; ARTICLE; BINDING SITE; CANCER CELL; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CANCER INVASION; CELL CYCLE; CELL GROWTH; CELL INVASION; CELL MIGRATION; CELL VIABILITY; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; FLOW CYTOMETRY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROSTATE EPITHELIUM; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN TARGETING; RNA BINDING; WESTERN BLOTTING;

CELL CYCLE; CELL LINE, TUMOR; CELL MOVEMENT; CELL NUCLEUS; CELL PROLIFERATION; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; MALE; MICRORNAS; NEOPLASM INVASIVENESS; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-ETS;

EID: 79961129083     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21389     Document Type: Article

References (46)

1. Hsu T, Trojanowska M, Watson DK,. Ets proteins in biological control and cancer. J Cell Biochem 2004; 91 (5): 896-903.
2. Turner DP, Findlay VJ, Moussa O, Watson DK,. Defining ETS transcription regulatory networks and their contribution to breast cancer progression. J Cell Biochem 2007; 102 (3): 549-559. (Pubitemid 47557410)
3. Turner DP, Watson DK,. ETS transcription factors: Oncogenes and tumor suppressor genes as therapeutic targets for prostate cancer. Expert Rev Anticancer Ther 2008; 8 (1): 33-42.
4. Watson DK, Turner DP, Scheiber MN, Findlay VJ, Watson PM,. ETS transcription factor expression and conversion during prostate and breast cancer progression. Open Cancer J 2010; 3: 24-39.
5. Sementchenko VI, Watson DK,. Ets target genes: Past, present and future. Oncogene 2000; 19 (55): 6533-6548. (Pubitemid 32108443)
6. Seth A, Watson DK,. ETS transcription factors and their emerging roles in human cancer. Eur J Cancer 2005; 41 (16): 2462-2478. (Pubitemid 41540623)
7. Feldman RJ, Sementchenko VI, Watson DK,. The epithelial-specific Ets factors occupy a unique position in defining epithelial proliferation, differentiation, and carcinogenesis. Anticancer Res 2003; 23 (3A): 2125-2132.
8. Oettgen P, Finger E, Sun Z, Akbarali Y, Thamrongsak U, Boltax J, Grall F, Dube A, Weiss A, Brown L, Quinn G, Kas K, Endress G, Kunsch C, Libermann TA,. PDEF, a novel prostate epithelium-specific ets transcription factor, interacts with the androgen receptor and activates prostate-specific antigen gene expression. J Biol Chem 2000; 275 (2): 1216-1225. (Pubitemid 30051174)
9. Feldman RJ, Sementchenko VI, Gayed M, Fraig MM, Watson DK,. Pdef expression in human breast cancer is correlated with invasive potential and altered gene expression. Cancer Res 2003; 63 (15): 4626-4631. (Pubitemid 36951040)
10. Ghadersohi A, Pan D, Fayazi Z, Hicks DG, Winston JS, Li F,. Prostate-derived Ets transcription factor (PDEF) downregulates survivin expression and inhibits breast cancer cell growth in vitro and xenograft tumor formation in vivo. Breast Cancer Res Treat 2007; 102 (1): 19-30.
11. Gu X, Zerbini LF, Otu HH, Bhasin M, Yang Q, Joseph MG, Grall F, Onatunde T, Correa RG, Libermann TA,. Reduced PDEF expression increases invasion and expression of mesenchymal genes in prostate cancer cells. Cancer Res 2007; 67 (9): 4219-4226. (Pubitemid 46815068)
12. Turner DP, Moussa O, Sauane M, Fisher PB, Watson DK,. Prostate-derived ETS factor is a mediator of metastatic potential through the inhibition of migration and invasion in breast cancer. Cancer Res 2007; 67 (4): 1618-1625. (Pubitemid 46383387)
13. Ghadersohi A, Odunsi K, Zhang S, Azrak RG, Bundy BN, Manjili MH, Li F,. Prostate-derived Ets transcription factor as a favorable prognostic marker in ovarian cancer patients. Int J Cancer 2008; 123 (6): 1376-1384.
14. Turner DP, Findlay VJ, Kirven AD, Moussa O, Watson DK,. Global gene expression analysis identifies PDEF transcriptional networks regulating cell migration during cancer progression. Mol Biol Cell 2008; 19 (9): 3745-3757.
15. Moussa O, Turner DP, Feldman RJ, Sementchenko VI, McCarragher BD, Desouki MM, Fraig M, Watson DK,. PDEF is a negative regulator of colon cancer cell growth and migration. J Cell Biochem 2009; 108 (6): 1389-1398.
16. Adams EJ, Green JA, Clark AH, Youngson JH,. Comparison of different scoring systems for immunohistochemical staining. J Clin Pathol 1999; 52 (1): 75-77. (Pubitemid 29023513)
17. Nowak DE, Tian B, Brasier AR,. Two-step cross-linking method for identification of NF-kappaB gene network by chromatin immunoprecipitation. Biotechniques 2005; 39 (5): 715-725.
18. D'Orazio D, Besser D, Marksitzer R, Kunz C, Hume DA, Kiefer B, Nagamine Y,. Cooperation of two PEA3/AP1 sites in uPA gene induction by TPA and FGF-2. Gene 1997; 201 (1-2): 179-187. (Pubitemid 27504092)
19. Findlay VJ, Turner DP, Moussa O, Watson DK,. MicroRNA-mediated inhibition of prostate-derived Ets factor messenger RNA translation affects prostate-derived Ets factor regulatory networks in human breast cancer. Cancer Res 2008; 68 (20): 8499-8506.
20. Nozawa M, Yomogida K, Kanno N, Nonomura N, Miki T, Okuyama A, Nishimune Y, Nozaki M,. Prostate-specific transcription factor hPSE is translated only in normal prostate epithelial cells. Cancer Res 2000; 60 (5): 1348-1352. (Pubitemid 30152005)
21. Tsujimoto Y, Nonomura N, Takayama H, Yomogida K, Nozawa M, Nishimura K, Okuyama A, Nozaki M, Aozasa K,. Utility of immunohistochemical detection of prostate-specific Ets for the diagnosis of benign and malignant prostatic epithelial lesions. Int J Urol 2002; 9 (3): 167-172. (Pubitemid 34535474)
22. Sood AK, Saxena R, Groth J, Desouki MM, Cheewakriangkrai C, Rodabaugh KJ, Kasyapa CS, Geradts J,. Expression characteristics of prostate-derived Ets factor support a role in breast and prostate cancer progression. Human Pathol 2007; 38 (11): 1628-1638. (Pubitemid 47589085)
23. Johnson TR, Koul S, Kumar B, Khandrika L, Venezia S, Maroni PD, Meacham RB, Koul HK,. Loss of PDEF, a prostate-derived Ets factor is associated with aggressive phenotype of prostate cancer: Regulation of MMP 9 by PDEF. Mol Cancer 2010; 9: 148.
24. Sementchenko VI, Watson DK,. Ets target genes: Past, present and future. Oncogene 2000; 19: 6533-6548. (Pubitemid 32108443)
25. Altieri DC,. Survivin and IAP proteins in cell-death mechanisms. Biochem J 2010; 430 (2): 199-205.
26. Koike H, Sekine Y, Kamiya M, Nakazato H, Suzuki K,. Gene expression of survivin and its spliced isoforms associated with proliferation and aggressive phenotypes of prostate cancer. Urology 2008; 72 (6): 1229-1233.
27. Kehinde EO, Maghrebi MA, Anim JT,. The importance of determining the aggressiveness of prostate cancer using serum and tissue molecular markers. Can J Urol 2008; 15 (2): 3967-3974.
28. Thiery JP, Acloque H, Huang RY, Nieto MA,. Epithelial-mesenchymal transitions in development and disease. Cell 2009; 139 (5): 871-890.
29. Chen M, Chen LM, Chai KX,. Androgen regulation of prostasin gene expression is mediated by sterol-regulatory element-binding proteins and SLUG. Prostate 2006; 66 (9): 911-920. (Pubitemid 43849590)
30. Emadi Baygi M, Soheili ZS, Essmann F, Deezagi A, Engers R, Goering W, Schulz WA,. Slug/SNAI2 regulates cell proliferation and invasiveness of metastatic prostate cancer cell lines. Tumour Biol 2010; 31 (4): 297-307.
31. Kurrey NK, Jalgaonkar SP, Joglekar AV, Ghanate AD, Chaskar PD, Doiphode RY, Bapat SA,. Snail and slug mediate radioresistance and chemoresistance by antagonizing p53-mediated apoptosis and acquiring a stem-like phenotype in ovarian cancer cells. Stem cells (Dayton, Ohio) 2009; 27 (9): 2059-2068.
32. Kajita M, McClinic KN, Wade PA,. Aberrant expression of the transcription factors snail and slug alters the response to genotoxic stress. Mol Cell Biol 2004; 24 (17): 7559-7566. (Pubitemid 39121483)
33. Gupta A, Lotan Y, Ashfaq R, Roehrborn CG, Raj GV, Aragaki CC, Montorsi F, Shariat SF,. Predictive value of the differential expression of the urokinase plasminogen activation axis in radical prostatectomy patients. Eur Urol 2009; 55 (5): 1124-1133.
34. Kumano M, Miyake H, Muramaki M, Furukawa J, Takenaka A, Fujisawa M,. Expression of urokinase-type plasminogen activator system in prostate cancer: Correlation with clinicopathological outcomes in patients undergoing radical prostatectomy. Urol Oncol 2009; 27 (2): 180-186.
35. Ahmad A, Kong D, Sarkar SH, Wang Z, Banerjee S, Sarkar FH,. Inactivation of uPA and its receptor uPAR by 3,3'-diindolylmethane (DIM) leads to the inhibition of prostate cancer cell growth and migration. J Cell Biochem 2009; 107 (3): 516-527.
36. Helenius MA, Saramaki OR, Linja MJ, Tammela TL, Visakorpi T,. Amplification of urokinase gene in prostate cancer. Cancer Res 2001; 61 (14): 5340-5344. (Pubitemid 32694906)
37. Fromont G, Chene L, Vidaud M, Vallancien G, Mangin P, Fournier G, Validire P, Latil A, Cussenot O,. Differential expression of 37 selected genes in hormone-refractory prostate cancer using quantitative taqman real-time RT-PCR. Int J Cancer 2005; 114 (2): 174-181. (Pubitemid 40194283)
38. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, Downing JR, Jacks T, Horvitz HR, Golub TR,. MicroRNA expression profiles classify human cancers. Nature 2005; 435 (7043): 834-838. (Pubitemid 40839735)
39. O'Donnell KA, Wentzel EA, Zeller KI, Dang CV, Mendell JT,. c-Myc-regulated microRNAs modulate E2F1 expression. Nature 2005; 435 (7043): 839-843. (Pubitemid 40839736)
40. Roldo C, Missiaglia E, Hagan JP, Falconi M, Capelli P, Bersani S, Calin GA, Volinia S, Liu CG, Scarpa A, Croce CM,. MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors are associated with distinctive pathologic features and clinical behavior. J Clin Oncol 2006; 24 (29): 4677-4684. (Pubitemid 46630931)
41. Zanette DL, Rivadavia F, Molfetta GA, Barbuzano FG, Proto-Siqueira R, Silva WA, Jr., Falcao RP, Zago MA,. miRNA expression profiles in chronic lymphocytic and acute lymphocytic leukemia. Braz J Med Biol Res (Rev Bras Pesquisas Med Biol/Soc Bras Biofis) 2007; 40 (11): 1435-1440. (Pubitemid 350302855)
42. Jukic DM, Rao UN, Kelly L, Skaf JS, Drogowski LM, Kirkwood JM, Panelli MC,. Microrna profiling analysis of differences between the melanoma of young adults and older adults. J Transl Med 2010; 8: 27.
43. Wu W, Lin Z, Zhuang Z, Liang X,. Expression profile of mammalian microRNAs in endometrioid adenocarcinoma. Eur J Cancer Prev 2009; 18 (1): 50-55.
44. Lee Y, Yang X, Huang Y, Fan H, Zhang Q, Wu Y, Li J, Hasina R, Cheng C, Lingen MW, Gerstein MB, Weichselbaum RR, Xing HR, Lussier YA,. Network modeling identifies molecular functions targeted by miR-204 to suppress head and neck tumor metastasis. PLoS Comput Biol 2010; 6 (4): e1000730.
45. Volinia S, Galasso M, Costinean S, Tagliavini L, Gamberoni G, Drusco A, Marchesini J, Mascellani N, Sana ME, Abu Jarour R, Desponts C, Teitell M, Baffa R, Aqeilan R, Iorio MV, Taccioli C, Garzon R, Di Leva G, Fabbri M, Catozzi M, Previati M, Ambs S, Palumbo T, Garofalo M, Veronese A, Bottoni A, Gasparini P, Harris CC, Visone R, Pekarsky Y, de la Chapelle A, Bloomston M, Dillhoff M, Rassenti LZ, Kipps TJ, Huebner K, Pichiorri F, Lenze D, Cairo S, Buendia MA, Pineau P, Dejean A, Zanesi N, Rossi S, Calin GA, Liu CG, Palatini J, Negrini M, Vecchione A, Rosenberg A, Croce CM,. Reprogramming of miRNA networks in cancer and leukemia. Genome Res 2010; 20 (5): 589-599.
46. Bussemakers MJ, van Bokhoven A, Verhaegh GW, Smit FP, Karthaus HF, Schalken JA, Debruyne FM, Ru N, Isaacs WB,. D D3: A new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res 1999; 59 (23): 5975-5979. (Pubitemid 30004960)